Acknowledgement

This activity is provided by Talem Health and ACCESS Oncology.


This activity is co-supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Credit Available

• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

Target Audience

This activity is designed specifically for oncology nurses, nurse practitioners, and other nursing professionals who provide cancer care in community and non-academic settings. 

Program Overview

Breast cancer affects approximately 1 in 8 women in the United States during their lifetime, and many individuals experience recurrent or metastatic disease. In recent years, antibody-drug conjugates (ADCs), a novel class of cancer therapeutics, have transformed the treatment landscape for breast cancer. However, disparities in access to high-quality cancer care persist in community-based settings. Oncology nurses play a critical role in improving outcomes for these patients by recognizing and managing treatment-related adverse events, supporting individualized care, and helping to overcome barriers to treatment access. In this CE activity, expert faculty will review the evolving role of ADCs in breast cancer management and discuss practical nursing considerations for monitoring safety, optimizing patient education, and improving delivery of patient-centered care in community oncology settings.

The content for this enduring activity was recorded during a live webinar on June 27, 2026.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Evaluate the benefits and safety profiles of new and emerging ADCs for breast cancer 
• Apply evidence-based strategies and best practices to identify, monitor, and mitigate adverse events associated with ADC therapies for breast cancer 
• Integrate strategies to improve communication, care coordination, and education for patients with breast cancer being treated with ADCs

Faculty

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology-Baylor
Charles A. Sammons Cancer Center
Dallas, TX

Lance F. Ortega, MBA, BSN, RN, OCN 
Executive Director, Clinical Operations  
Texas Oncology 
Dallas-Fort Worth, TX 

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


 

Credit Designation Statement

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP, has disclosed the following relevant financial relationships: consultant/advisory board member for Amplity and Kaplan; speakers’ bureau/honoraria from AstraZeneca Pharmaceuticals, Biotheranostics, Inc., Daiichi Sankyo, Inc., and Stemline Therapeutics, Inc.
 
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose. 

Planners, Managers, and Reviewer 
None of the Talem Health staff (planners, managers, or reviewer) for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. 

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CE credit, participants must: 

1. Read the CE information, including learning objectives and disclosure statements. 
2. Complete the pre-test. 
3. View the online activity. 
4. Complete the post-test and evaluation form. 

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download. 

Course Viewing Requirements 

Supported Browsers: 
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets: 
All devices

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©ACCESS Oncology, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact ACCESS Oncology (a division of Talem Health) at 800-913-9370 or cme@accessoncologyce.com.